CGTLive’s Weekly Rewind – November 18, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

The director of the CCU/ICU at Saint John’s Health Center discussed unmet respiratory treatment needs in the beginning of the COVID-19 pandemic.

Updated data from a first-in-human trial were presented at the SITC 2022 meeting.

Sarnaik discussed the investigational TIL therapy’s potential as an additional option for patients.

CAN-2409 transduces tumor cells with the thymidine kinase gene, sensitizes these cells to valacyclovir, and stimulates patients’ immune response.